India

Zydus Cadila Covid Vaccine: India approves first vaccine for kids; world’s first Covid-19 vaccine using DNA tech | India News

India’s drug regulator has given emergency approval to Zydus Cadila’s vaccine, making it the world’s first Covid-19 vaccine using DNA platform, the first vaccine for children above 12 years in India, and the sixth vaccine for use in adults here.
Till now vaccines which are in trials or are approved globally use either the whole virus (Bharat Biotech), protein subunit (Novavax), viral vector (AstraZeneca/ Serum and J&J) or messenger RNA (Pfizer and Moderna) technology platform. (Novavax has not been approved yet).
Zydus Cadila announced that it has received emergency use authorization for its Covid-19 vaccine, ZyCoV-D, for adolescents in the 12-18 age group, besides the adult population.
This could become the first Covid-19 vaccine to be rolled out for adolescents in India, with others like Novavax still in clinical trials, and J&J yet to start a local study of its vaccine on kids.
ZyCoV-D is a three-dose vaccine which will be administered first on day zero, day 28th and then the 56th day. It is a needle-free vaccine administered using a special device, `PharmaJet’, which ensures painless intradermal vaccine delivery, the company said.
To start with, the company will supply around 10 million doses in a month. The company expects to roll out supplies from October, once the government has placed the order.
Pankaj R Patel, chairman, Cadila Healthcare told TOI the vaccine showed 66% efficacy against moderate Covid infection, and 100% against severe Covid, preventing serious disease and hospitalization. The clinical trials were conducted on over 28,000 subjects, including kids, and were done when the Delta variant was prevalent across the country.
The company plans to manufacture 10-12 crore doses of ZyCoV-D annually, and has started stockpiling the vaccine.
The platform because of its rapid plug and play technology can be easily adapted to deal with mutations in the virus, such as those already occurring, a statement from the company said.
“This is a historic milestone with ZyCoV-D, a product of Indian innovation becoming the world’s first DNA vaccine being offered for human use and supporting the world’s largest immunization drive. We are particularly happy that our vaccine will contribute to this fight against Covid-19 and enable the country to vaccinate a larger population especially in the age group of 12-18 years’’, Patel added.
India approves first vaccine for kids; world’s first Covid-19 vaccine using DNA tech.
India’s drug regulator has given emergency approval to Zydus Cadila’s vaccine, making it the world’s first Covid-19 vaccine using DNA platform, the first vaccine for children above 12 years in India, and the sixth vaccine for use in adults here.
Till now vaccines which are in trials or are approved globally use either the whole virus (Bharat Biotech), protein subunit (Novavax), viral vector (AstraZeneca/ Serum and J&J) or messenger RNA (Pfizer and Moderna) technology platform. (Novavax has not been approved yet).
Zydus Cadila announced that it has received emergency use authorization for its Covid-19 vaccine, ZyCoV-D, for adolescents in the 12-18 age group, besides the adult population.
This could become the first Covid-19 vaccine to be rolled out for adolescents in India, with others like Novavax still in clinical trials, and J&J yet to start a local study of its vaccine on kids.
ZyCoV-D is a three-dose vaccine which will be administered first on day zero, day 28th and then the 56th day. It is a needle-free vaccine administered using a special device, `PharmaJet’, which ensures painless intradermal vaccine delivery, the company said.
To start with, the company will supply around 10 million doses in a month. The company expects to roll out supplies from October, once the government has placed the order.
Pankaj R Patel, chairman, Cadila Healthcare told TOI the vaccine showed 66% efficacy against moderate Covid infection, and 100% against severe Covid, preventing serious disease and hospitalization. The clinical trials were conducted on over 28,000 subjects, including kids, and were done when the Delta variant was prevalent across the country.
The company plans to manufacture 10-12 crore doses of ZyCoV-D annually, and has started stockpiling the vaccine.
The platform because of its rapid plug and play technology can be easily adapted to deal with mutations in the virus, such as those already occurring, a statement from the company said.
“This is a historic milestone with ZyCoV-D, a product of Indian innovation becoming the world’s first DNA vaccine being offered for human use and supporting the world’s largest immunization drive. We are particularly happy that our vaccine will contribute to this fight against Covid-19 and enable the country to vaccinate a larger population especially in the age group of 12-18 years,” Patel added.




Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button